Windlas Biotech Ltd Announces Q2 and H1 Results for FY2025: Revenue from Operations at INR 2,223.98 Million

Windlas Biotech Ltd, a leading pharmaceutical company, has announced its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025. The company reported a revenue from operations of INR 2,223.98 million, an increase from the previous quarter. The total income expenses for the quarter were INR 2,117.53 million. The profit before tax stood at INR 235.88 million. The company reported a profit for the year of INR 178.00 million. The consolidated unaudited financial results included the financial results of one subsidiary, Windlas Inc., USA, which have not been reviewed by their auditors. The company has also introduced 'Windlas Plan 2025' to grant options/units to eligible employees.